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ABSTRACT
Background. In hypertrophic cardiomyopathy (HC) the clinical significance attributable to the broad range in left ventricular (LV) systolic function, assessed as ejection fraction (EF), is incompletely resolved. Objective. To evaluate EF by cardiovascular magnetic resonance (CMR) in a large cohort of HC patients with respect to clinical status and evidence of left ventricular remodelling with late gadolinium enhancement (LGE). Methods. CMR was performed in 310 consecutive patients, age 42±17 years. Results. EF in HC patients was 71±10% (range 28-89%), exceeding that of 606 healthy controls without cardiovascular disease (66±5%, p<0.001). LGE reflecting LV remodelling showed an independent, inverse relationship with EF (B-0.69; 95% CI -0.86 to -0.52; p<0.001) and was greatest in patients with EF <50%, in whom it constituted 27±13% of LV volume. However, also the substantial subgroup with low-normal EF values of 50-65% (n=45; 15% of the whole cohort), mostly asymptomatic or mildly symptomatic (37 or 82% in NYHA functional class I/II), showed substantial LGE (8±11% of LV volume), which overlapped the subgroup with systolic dysfunction and significantly exceeded that of patients with EF 66-75% (LGE 4±6%) and >75% (LGE 3±4%; p<0.01). Conclusions. In a large HC cohort, a subset of patients with low-normal EF values  (50-65%) was identified by contrast-enhanced CMR as having substantial degrees of LGE, suggesting a transition phase potentially heralding advanced LV remodeling and systolic dysfunction, with implications for clinical surveillance and management.
(Word count = 228).









	HC patients. The study population comprised 310 patients with HC consecutively referred for CMR between 2001 and 2008 at centers in Minneapolis and Boston (Table 1). Diagnosis of HC was based on CMR and two-dimensional echocardiographic evidence of a hypertrophied LV (maximal wall thickness 15 mm) with normal or small cavity size (defined by an end-diastolic volume index <75 ml/m2) (17), in the absence of another cardiac or systemic disease that could produce the magnitude of hypertrophy evident, at some time during the patient’s clinical course (1,2). None of our patients had significant CAD (defined as >50% stenosis in one major artery), as ascertained by specific clinical and/or CMR evidence. First, no patient had experienced an acute coronary event associated with increased cardiac enzymes or Q waves on ECG. Second, when LGE was present in a subendocardial or transmural distribution within a single coronary artery vascular territory, hemodynamically significant CAD was excluded by arteriography or CT angiogram (12). Patients with prior cardiac surgery or percutaneous alcohol septal ablation were excluded from the study. The study protocol was approved by the respective internal review board or research ethics committees of each participating institution, and written inform consent was obtained from each subject. Selected data from subsets in this patient cohort have been part of other analyses (10,12).
	Control subjects. A reference population of 606 healthy adult participants in the Framingham Heart Study Offspring Cohort (239 men; 367 women) without evidence of clinical cardiovascular disease were studied by CMR, using a scanning protocol similar to that reported here for patients with HC (18). Mean age was 61±8 years for both men and women. Body surface area was 2.0±0.2 m2 for males and 1.7±0.2 m2 for females. 
Echocardiography
Comprehensive two-dimensional and Doppler echocardiographic studies were performed in each patient using commercially available instruments (17). LV hypertrophy was assessed by two-dimensional echocardiography, and the site and extent of maximal wall thickness were identified (19). Peak instantaneous LV outflow gradient, due to mitral valve systolic anterior motion and mitral-septal contact, was estimated with continuous wave Doppler under basal conditions (20). Left atrial dimension was measured at end-systole in the anteroposterior linear diameter from the parasternal long-axis view (19).
Cardiovascular Magnetic Resonance (CMR) 
	All measurements on CMR studies in HC patients and controls were performed by a centralized core lab (PERFUSE Core Laboratory and Data Coordinating Center, Harvard Medical School, Boston), previously used in other studies (12). CMR imaging was performed (Philips Gyroscan ACS-NT 1.5T, Best, Netherlands and Siemens Sonata 1.5T, Erlangen, Germany) using steady-state, free precession breathhold cines in 3 long-axis planes and contiguous 10 mm (no gap) or 8 mm (2 mm gap) short-axis slices from the atrioventricular ring to apex. LGE images were acquired 15 minutes after the intravenous administration of 0.2 mmol/kg of gadolinium-DTPA (Magnevist, Schering; Berlin, Germany) with a breath-hold two-dimensional segmented inversion-recovery sequence acquired in the same views as the cine images. The inversion time (TI) ranged from 240-300 ms and was chosen to null normal myocardial signal. 
Left ventricular volumes, ejection fraction, mass, and wall thickness were analyzed with a commercial workstation (MASS®, version 6.1.6 Medis, Inc., Netherlands). The endocardial and epicardial borders of the LV were manually planimetered by an experienced observer (C.J.H.) on successive short-axis cine images at end-diastole, with only the endocardial border planimetered on the end-systolic frame. Ventricular volume and mass were derived by summation of discs, with mass calculated by multiplying myocardial muscle volume by 1.05 g/cm³. Ejection fraction was calculated by dividing LV stroke volume by the end-diastolic volume. Maximal LV wall thicknesses were taken as the greatest dimension determined automatically by the MASS software at any site within the LV wall. Anatomical parameters were normalized to body surface area.	
Late gadolinium images (LGE) images were acquired 10-15 minutes after intravenous administration of 0.2 mmol/kg gadolinium-DTPA (Magnevist, Schering; Berlin,Germany) with breath-held segmented inversion-recovery sequence, acquired in the same orientations as the cine images. An inversion time (TI) scout was used initially to find the optimal TI in order to null normal myocardium (typically 240 to 300 ms). 
To ascertain the presence of LGE, all tomographic short-axis LV slices from base to apex were inspected visually to identify an area of completely nulled myocardium. Mean signal intensity (and standard deviation) of normal myocardium was calculated and a threshold ≥6 SD exceeding the mean was used to define areas of LGE (3,12). The choice of 6 SD is based on our experience that semi-automated LGE-CMR gray-scale thresholding utilizing ≥ 6 SD above the mean of visually normal, remote myocardium is the most reliable method for assessing the extent of LGE in LV myocardium of patients with HC (21).
Total LGE volume (expressed in grams [g]) was calculated by summing the planimetered areas of LGE present on on each short-axis slice, and multiplying by the slice thickness (10 mm) it was expressed as a proportion of total LV myocardial volume (%LGE). 
Statistical methods




Relation of EF to clinical parameters
		Ejection fraction in the 310 HC patients was significantly greater than in the reference healthy control population (71±10% vs. 66±5%; p<0.001). Distribution of EF was <50% (overt systolic dysfunction; n=15; 5%), 50-65% (n=45; 15%), 66-75% (n=144; 46%) and >75% (n=106; 34%). Patients with EF <50% and with EF 50-65% showed similar transverse LV end-diastolic and left atrial dimensions, exceeding those of patients with EF 66-75% or >75% (Table 1). 
	In the overall study group, no significant relation was evident between EF and age, gender, body surface area, LV volumes, and maximal LV thickness or mass (Tables 1 and 2), nor between HC patients with and without treatment with beta-blockers (72±11% vs 70±8%, respectively; p=0.18), verapamil (73±10% vs 71±9%; p=0.09), or disopyramide  (73±3% vs 71±10%; p=0.48). Atrial fibrillation occurred more frequently in patients with EF <50%, compared to the other three EF subgroups (Table 1).
Relation of EF to LGE
	LGE was present in 157 of the 310 patients (51%)(Figures 1 and 2), and was located in either the ventricular septum (n=56), LV free wall (n=40) or both (n=61). In these 157 patients, LGE mass was 19±21 grams (range 1-83), representing 6±9% of the overall LV wall (Table 2). The % of LV volume occupied by LGE was inversely related to EF (R2=0.29, p<0.001)(Figure 1).  In a multivariate linear regression model including age, LV outflow gradient, left atrial size, and LV mass, %LV myocardium occupied by LGE was the only independent predictor of systolic dysfunction, showing a strong, inverse relationship to EF (B -0.69, 95% C.I.-0.86 to -0.52; p<0.001).
	In each of the 15 patients with overt systolic dysfunction (EF <50%; range 28-49%), LGE was diffusely distributed and constituted 27±13% of the LV (Figures 1 and 2). In patients with intermediate, low-normal EF values of 50-65%, LGE was also common (30/45 patients; 67%) and extensive (8±11% of LV), ranging from limited (≤5% of LV; n=10 patients) to substantial (>15% of LV volume; n=8 patients) (Figure 1). LGE values in the latter 8 patients (representing 17% of the EF 50-65% group), overlapped with those observed in the EF <50% subgroup (Figure 2). Conversely, among patients with intact systolic function and EF >65%, LGE was present in less than one-half (110/250; 44%; p<0.01 vs. EF 50-65%), was limited in magnitude (4±5% of LV), with no significant difference between the 66-75% and >75% EF subgroups (Table 2).

DISCUSSION
Spectrum and determinants of LV systolic function 
	Remodelling of the LV chamber in HC has been shown to occur in several clinical circumstances, including progression of LV hypertrophy during adolescence (21), and evolution to the end-stage with overt systolic dysfunction (3-7). In the present cross-sectional analysis, we employed CMR in a large consecutive HC cohort to examine the relationship of ejection fraction to a variety of clinical variables potentially relevant to LV remodeling and systolic performance. 
	In our HC cohort, EF values encompassed a broad range, from hyperdynamic to impaired, but on average significantly exceeded that in healthy controls, consistent with the view that HC is a disease often expressed by a hypercontractile LV (1,2). However, we found little or no relationship between CMR-measured EF and several standard clinical and demographic parameters such as age, gender, LV cavity dimension and LV wall thickness or mass. On the other hand, our contrast-enhanced CMR studies demonstrated that LV remodeling expressed by LGE, generally regarded as an in vivo representation of myocardial replacement fibrosis (3,11,16), is relevant to systolic function in HC. Indeed, we not only confirmed an  inverse relationship of EF to LGE (12), but also showed LGE to be the only independent predictor of systolic dysfunction in a multivariate model which included several other potentially relevant clinical variables. Patients with the lowest EF (i.e., with overt systolic dysfunction) demonstrated the most extensive and diffusely distributed LGE, while those with supernormal LV systolic function had minimal LGE. 
	Most importantly, the substantial size of the present study cohort permitted several EF subsets of sufficient size to be analyzed and compared. Given this advantage, we were able to discern that the extent of myocardial fibrosis was considerable in the relatively small but potentially important subgroup of patients with low-normal EF values of 50-65%. In this subgroup, LGE occupied almost 10% of the LV myocardium, i.e. was significantly greater than that seen in patients with hyperdynamic LV function, and substantially overlapped with patients exhibiting overt systolic dysfunction (EF<50%). This finding suggests that we have likely identified evidence of advanced fibrosis and LV remodeling in HC patients with low-normal EF that could potentially represent a transition phase in evolution to the end-stage phase (3-7). 
	The LV remodelling described here may represent the long-term consequence of microvascular ischemia causing myocyte death and with the sequelae of replacement fibrosis as a repair process, ultimately leading selected patients to progressive systolic impairment (3,7,23,24). Based on LGE analysis, we thus hypothesize that patients in the 50-65% EF subgroup with substantial evidence of myocardial fibrosis can be regarded as pre-end-stage. This concept is also supported by the observation that the EF 50-65% subset is more similar to the EF <50% subgroup, with respect to relevant clinical variables such as LV chamber and left atrial size and low prevalence of obstruction (1,3,25), than to those patients with intact systolic function (EF >65%).  
Clinical implications
	The findings of the present study have potential implications for the natural history and long-term management strategies of patients with HC. In this regard, EF in the 50-65% range, in the presence of substantial LGE, may raise clinical suspicion of ongoing LV remodeling potentially associated with declining LV systolic function (3,12). Therefore, close clinical and imaging surveillance, including assessment of EF and LGE progression, would seem prudent (3,6). Indeed, disease progression may occur in HC over extended periods (6,7) and anticipation of developing systolic dysfunction is potentially important in a number of respects, to permit timely intervention with specific pharmacologic strategies including modulators of the renin-angiotensin system and beta-blockers (2). Furthermore, selected patients with marked disease progression and LV remodeling --- i.e. those entering the end-stage phase, may eventually become candidates for primary prevention of sudden death with implantable defibrillators (2,3), and evaluation for future heart transplantion  (4). 
	The cross-sectional nature of the present study limits our ability to be definitive regarding the possible transition from intact or borderline to impaired systolic function, which will require long periods of follow-up not yet available given the relatively recent introduction of CMR to HC (8,10). Indeed, we would not expect the majority of patients in the low-normal EF subgroup to ultimately develop overt systolic dysfunction, since the prevalence of end-stage disease does not exceed 5% in most HC study cohorts (3-5), whereas our 50-65% EF subset was three-fold larger at 15%. Nevertheless, this subset with intermediate degrees of remodeling and initial dysfunction is likely to represent the “pool” of candidates to disease progression, deserving closer follow-up. Larger availability of CMR and dedicated longitudinal studies on HC patients will hopefully lead to more precise identification of potential predictors of disease progression. 
Conclusions
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Figure 1: Relationship of LV ejection fraction to frequency and extent of contrast-CMR delayed enhancement (LGE) in 310 patients with HC. Left panel. Prevalence of LGE in four EF subgroups. Right panel. Mean LGE (±SD), expressed as % of overall LV myocardial volume, in the same subgroups. 
 








Table 1.  Clinical, demographic and echocardiographic findings with respect to LV ejection fraction in 310 HC patients.
For Table 1

Abbreviations: ACE= angiotensin converting enzyme; CAD = coronary artery disease; EF = ejection fraction; ICD = implantable cardioverter defibrillator; LV = left ventricular; LVOT = LV outflow tract; MR = mitral regurgitation; NYHA = New York Heart Association.
Symbols: *= p<0.05 versus all other groups; ¶ = p<0.05 vs 50-65%; † = p<0.05 vs. 66-75%; ‡ = p<0.001 vs. >75% .





Abbreviations: LGE =  late gadolinium enhancement; LV = left ventricular; n.a. = not applicable.




Clinical / Demographic Data	Overall	<50%	50-65%	66-75%	>75% 	P- value
No. of Patients	310	15	45	144	106	
Male	218 (70%)	9 (60%)	33 (73%)	110 (76%)	66 (62%)	0.08
Age at study entry (y)	42±17	43±17	40±17	41±18	46±17	0.12
Age at diagnosis (y)	37±17	30±17	35±15	36±18	41±16	0.04
Initial NYHA functional class	1.3±0.6	1.5±05	1.4±0.6	1.2±0.5	1.4±0.6	0.08
In NYHA Class I/II	264 (85%)	12 (80%)	37 (82%)	125 (87%)	90 (85%)	0.12
Angina	109 (35%)	3 (20%)	17 (38%)	51 (35%)	38 (36%)	0.64
Syncope	68 (22%)	4 (27%)	10 (22%)	30 (21%)	24 (23%)	0.95
Atrial fibrillation	39 (13%)	6 (40%)*	5 (11%)	19 (13%)	9 (8%)	0.019
Medical treatment	220 (71%)	13 (87%)	24 (53%)	92 (64%)	91 (86%)¶†	<0.01
       Beta-blockers	179 (58%)	12 (80%)	19 (42%)	76 (53%)	72 (68%)¶	0.004
       Verapamil	65 (21%)	2 (13%)	8 (18%)	26 (18%)	29 (27%)	0.24
       Amiodarone	6 (2%)	2 (13%)‡	0	3 (2%)	1 (1%)	0.008
       Disopyramide	7 (2%)	0	0	6 (4%)	1 (1%)	0.20
       Diuretics	38 (12%)	5 (33%)†	3 (7%)	11 (8%)	19 (18%)	0.004
       ACE-inhibitors	39 (13%)	6 (40%)*	5 (11%)	14 (10%)	14 (13%)	0.01
Systemic hypertension	72 (23%)	3 (20%)	10 (22%)	30 (21%)	29 (27%)	0.66
ICD	59 (19%)	7 (47%)†‡	11 (24%)	23 (16%)	18 (17%)	0.03
Echocardiography						
Left atrium (mm)	42±8	45±10	44±7	41±8	42±7	0.22
Max.LV wall thickness (mm)	21±6	21±7	21±7	21±6	21±5	0.91
LV End-diastolic diameter (mm)	44±7	48±11‡	47±6‡	44±6	43±7	0.002
LVOT obstruction  at rest (≥ 30 mmHg)	61 (20%)	0	7 (16%)‡	24 (17%)	30 (28%)	0.03





No. of Patients	310	15 	45	144	106	
Age at  study entry (y)	42±17	43±17	40±17	41±18	46±17	0.12
Body surface area (m2)	1.9±0.3	1.9±0.3	2.0±0.3	1.9±0.3	1.9±0.3	0.74
Body mass index (kg/m2)	29±7	29±4	31±9	28±6	30±7	0.10
LV end-diastolic volume (ml)	161±45	197±61†‡	167±48	162±46	153±36	0.003
LV end-diastolic volume index (ml/m2)	83±18	104±29*	84±19	83±17	79±16	<0.001
LV end-systolic volume (ml)	47±24	114±35*	65±19†‡	47±14‡	31±9	<0.001
LV end-systolic volume index (ml/m2 )	24±12	60±19*	32±8†‡	24±6‡	16±4	<0.001
LV mass (g)	203±85	264±142†‡	214±99	195±78	200±75	0.02
LV mass index (g/m2)	103±38	137±64*	107±46	99±34	102±33	0.002
LV mass/volume ratio	 1.3±0.5	1.4±0.6	1.3±0.6	1.2±0.4	1.3±0.5	0.24
LV ejection fraction (%)	71±10	42±7	61±4	71±3	80±3	n.a.
Presence of LGE	157 (51%)	15 (100%)	30 (67%)	60 (42%)	50 (47%)	0.001
LGE mass (gr)	19±21	49±21*	22±24	17±18	12±13	<0.001
LGE mass (% of whole LV)	6±9	27±13*	8±11‡	4±6	3±4	<0.001
 












